Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 15/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 2/20 | 0.68 |
| ▸ | ACHE | P22303 | 4/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | CASP7 | P55210 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563825 | 0.85 | SMN1; SMN2 (0.74) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL11391879 | 0.84 | SMN1; SMN2 (0.73) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL31478721 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL11399753 | 0.83 | SMN1; SMN2 (0.71) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL11396751 | 0.83 | MAOB (0.71) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL28682651 | 0.82 | MAOB (0.70) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL6933429 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL1607327 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL3283803 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL17664186 | 0.80 | MAOB (0.68) | KDM4EALDH1A1SMN1; SMN2HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109464441-B | Application of 3-acetamido coumarin in preparing medicine for treating or preventing hyperuricemia and kidney injury | 北京大学 | 2021-04-23 | — | — | CN | claimed |
| EP-2665739-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2012100248-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | claimed |
| US-20120114670-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | UNIVERSITY OF ROCHESTER (US) | 2012-05-10 | — | — | US | claimed |
| US-20120082659-A1 | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-05 | — | — | US | claimed |
| US-20100285001-A1 | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations | UNIVERSITY OF ROCHESTER (US) | 2010-11-11 | — | — | US | claimed |
| WO-2006024545-A1 | FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2006-03-09 | — | — | WO | claimed |
| US-12409161-B2 | Compound for treating neurodegenerative disorders | FUDAN UNIVERSITY (CN) | 2025-09-09 | — | — | US | disclosed |
| CN-113891711-B | Compounds for the treatment of neurodegenerative diseases | 复旦大学 | 2024-11-15 | — | — | CN | disclosed |
| US-20220249433-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | FUDAN UNIVERSITY (CN) | 2022-08-11 | — | — | US | disclosed |
| US-20220249433-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | FUDAN UNIVERSITY (CN) | 2022-08-11 | — | — | US | disclosed |
| EP-3954368-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | Fudan University (CN) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954368-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | Fudan University (CN) | 2022-02-16 | — | — | EP | disclosed |
| WO-2003011935-A2 | MODIFIED AMINOPLAST CROSSLINKERS AND POWDER COATING COMPOSITIONS CONTAINING SUCH CROSSLINKERS | PPG INDUSTRIES OHIO, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011932-A1 | MODIFIED AMINOPLAST CROSSLINKERS AND POWER COATING COMPOSITIONS CONTAINING SUCH CROSSLINKERS | PPG INDUSTRIES OHIO, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020132935-A1 | Modified aminoplast crosslinkers and powder coating compositions containing such crosslinkers | PPG INDUSTRIES OHIO, INC. | 2002-09-19 | — | — | US | disclosed |
| US-20020071955-A1 | Modified aminoplast crosslinkers and powder coating compositions containing such crosslinkers | PPG INDUSTRIES OHIO, INC. | 2002-06-13 | — | — | US | disclosed |
| US-20020040112-A1 | Modified aminoplast crosslinkers and powder coating compositions containing such crosslinkers | PPG INDUSTRIES OHIO, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20020037973-A1 | Modified aminoplast crosslinkers and powder coating compositions containing such crosslinkers | PPG INDUSTRIES OHIO, INC. | 2002-03-28 | — | — | US | disclosed |
| US-3968119-A | OPTICAL BRIGHTENERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409161-B2 | Compound for treating neurodegenerative disorders | HTT, MAPT, SNCA | KDM4E 3307/4885ALDH1A1 3476/4885SMN1; SMN2 8/4885 |
| US-20220249433-A1 | COMPOUND FOR TREATING NEURODEGENERATIVE DISORDERS | HTT, MAPT, SNCA | KDM4E 3307/4885ALDH1A1 3476/4885SMN1; SMN2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.